Jenny Sundqvist

Jenny Sundqvist

Chief Commercial Officer

Jenny Sundqvist leads the licensing and commercialization efforts of the company’s lead drug candidate arfolitixorin. Ms Sundqvist has an impressive commercial career in consumer goods, medical device and over 16 years in the pharmaceutical industry. Having a strong international background, Ms Sundqvist has always worked in global roles. Just prior to joining Isofol, Ms Sundqvist was accountable for the oncology portfolio at AstraZeneca. Ms Sundqvist has a BSc in International Trade & Finance from Louisiana State University and an MBA from McCombs School of Business.

Jenny joined Isofol in 2021.

Position: Chief Commercial Officer

Holdings: 0 shares*, 49 134 warrants**

Phone: +46 (0)708-226378


*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of December 31, 2021.
** Isofol Medical AB (publ) warrent program 2018 series 2018/2022 and 2018/2023. For more information and terms read more under Corporate Governance.